Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus plus Danazol for Steroid-resistant/Relapse ITP
NCT05471050Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tacrolimus in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
tacrolimus
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05471050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471050.